RMH - CAR-T Treatment
The Royal Marsden NHS Foundation TrustcontractFind a Tender ↗Ref ocds-h6vhtk-05d335Procurement Act 2023SME suitableVCSE suitablepending
Estimated value
—
Awarded value
£380k
Suppliers
0
Lots
1
1 awarded
Published
24 Oct 2025
Description
CAR-T treatment called Obecel developed to treat relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (r/r B-ALL) which has recently become available to patients. The decision which treatment is most suitable applicable to a specific age group is a clinical one that would be decided by a Multi-Disciplinary Team (MDT). The product should meet strict NHS England standards for cryogenic storage and handling and RMH has such credentials.
Scope
- Reference
- ocds-h6vhtk-05d335
- Commercial tool
- Standalone contract
- Particular suitability
- Small and medium-sized enterprises (SME)Voluntary, community and social enterprises (VCSE)
Submission & procedure
- Procedure
- Direct award
Award details
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
£380k
Award date
—
Contract start
01 Nov 2025
Contract end
31 Oct 2026